Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 05 April 2017 | By Michael Mezher
The EU's effort to overhaul the regulation of medical devices and in vitro diagnostics (IVDs) has cleared its final legislative hurdle after the European Parliament on Wednesday adopted the proposed regulations without amendment, voting down a proposal from the UK Independence Party to reject the regulations.
The new regulations, which include stricter premarket review of high-risk devices, strengthened designation criteria for notified bodies, improved traceability, as well as a risk-based classification system for IVDs, are the result of a multi-year negotiation process between the European Commission, Parliament and Council to address gaps in oversight that led to several device-related scandals.
Now that the legislative process has concluded, the Medical Device Regulations (MDR) and In Vitro Diagnostics Regulations (IVDR) are set to be formally published in the Official Journal of the European Union in May.
Following publication, the new regulations for medical devices will enter into force in three years, and in five years for IVDs.
The European Commission praised the Parliament's move to adopt the two regulations, which came nearly four and a half years after the Commission first proposed to replace the existing directives governing devices and IVDs.
"The Commission heartily welcomes the final compromise which contains a series of crucial improvements to the current system," said European Commissioner of Health and Food Safety Vytenis Andriukaitis.
During debate on the two regulations on Tuesday, MEP and rapporteur for medical devices Glenis Willmott said the new regulations will improve patient safety going forward.
"The metal-on-metal hip scandal highlighted weaknesses in the current system. So we've introduced much stricter requirements for the bodies that authorize medical devices, and will insist that particularly high risk devices, such as implants, joint replacements or insulin pumps, be subject to additional expert assessments before they can be authorized," Willmott said.
European Parliament, Video
European Commission
Tags: MDR, IVDR, European Parliament
Regulatory Focus newsletters
All the biggest regulatory news and happenings.